Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with ...

The company will deliver an oral presentation on ADRX-0405, its clinical-stage STEAP1 ADC, and a poster presentation on ADRX-0134, its preclinical Na ...

Monomethyl auristatin E (MMAE) Payload is Likely to Dominate the Antibody Drug Conjugate Market During the Forecast Period Based on the type of payload, the market is segmented into Monomethyl ...

The ADC is a human IgG1 antibody conjugated at DAR8 with Adcentrx’s clinically validated AP052 tubulin inhibitor payload, substantially expanding the therapeutic window of auristatin-based ADCs beyond ...

The ADC is a human IgG1 antibody conjugated at DAR8 with Adcentrx's clinically validated AP052 tubulin inhibitor payload, substantially expanding the therapeutic window of auristatin-based ADCs ...

10,808,039 – which covers auristatin compounds coupled to an antibody via a linker molecule and had been challenged by Daiichi Sankyo. The Japanese drugmaker had filed a post-grant review ...

a fully human IgG2 anti-HER3 monoclonal antibody (mAb), which is site-specifically conjugated at glycan to the monomethyl auristatin E (MMAE) payload with a drug-to-antibody ratio (DAR ...

临床前研究表明，在卵巢癌模型中与标准化疗联合使用时，抗肿瘤效果得到显著改善。 DMOT4039A是一种人源化抗间皮素单克隆抗体与单甲基auristatin E（MMAE）偶联的ADC，具有抗有丝分裂作用，在I期临床试验中显示出良好的安全性。 CAR-T细胞 间皮素靶向CAR-T细胞的 ...

Indusatumab Vedotin（MLN-0264; AKT-264） 是一种 靶向 GCC（鸟苷酸环化酶 C） 的抗体-药物偶联物（ADC），由 人源化抗 GCC 单克隆抗体 通过 可裂解的连接子 偶联 微管破坏剂 MMAE（Monomethyl Auristatin E） 组成。 Indusatumab Vedotin 作用机制 靶向结合：Indusatumab Vedotin ...